Article in American journal of physiology. Heart and circulatory physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Brittany N LafaverDepartment of Biochemistry, University of Missouri School of Medicine, Columbia, Missouri, United States.ORCID 0000-0001-7246-841X
Li LeeDepartment of Radiology, University of Missouri School of Medicine, Columbia, Missouri, United States.ORCID 0000-0002-9510-8967
Chloe E DerocherHospital for Special Surgery, New York, New York, United States.
Lawrence F LevinHospital for Special Surgery, New York, New York, United States.
Erin M CarterHospital for Special Surgery, New York, New York, United States.ORCID 0009-0007-8754-6354
Krish SardesaiDepartment of Biomedical Sciences, School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, United States.ORCID 0000-0002-6213-8879
Julian A VallejoDepartment of Biomedical Sciences, School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, United States.
Ali McAllister-DayCollege of Veterinary Medicine, University of Missouri School of Medicine, Columbia, Missouri, United States.
Tara K CrawfordDepartment of Biochemistry, University of Missouri School of Medicine, Columbia, Missouri, United States.ORCID 0000-0001-9326-1661
Isabel M ChapmanDepartment of Biochemistry, University of Missouri School of Medicine, Columbia, Missouri, United States.
Michael J WackerDepartment of Biomedical Sciences, School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, United States.ORCID 0000-0002-1768-562X
Cathleen L RaggioHospital for Special Surgery, New York, New York, United States.
Lixin MaDepartment of Radiology, University of Missouri School of Medicine, Columbia, Missouri, United States.ORCID 0000-0003-2171-1226
Maike KrenzDepartment of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, Missouri, United States.
Charlotte L PhillipsDepartment of Biochemistry, University of Missouri School of Medicine, Columbia, Missouri, United States.ORCID 0000-0002-7761-3783
Funding
MOLECULAR BASIS OF GENE EXPRESSION AND SIGNAL PROCESSINGT32GM008396 · NIGMS · UNIVERSITY OF MISSOURI-COLUMBIA · PI HANNINK, MARK · 1991 to 2021
$4.1M
IMSD: An Initiative to Maximize Student Development in Biomedical Research at MUT32GM135744 · NIGMS · UNIVERSITY OF MISSOURI-COLUMBIA · PI SCHRUM, ADAM G. · 2020 to 2025
$2.6M
Maternal Anti-myostatin (GDF8) Therapy to Enhance Offspring Musculoskeletal Health in Mouse Models of Osteogenesis ImperfectaR21AR077813 · NIAMS · UNIVERSITY OF MISSOURI-COLUMBIA · PI PHILLIPS, CHARLOTTE L · 2020 to 2021
$368k
Charles Gerhke FellowshipHHS | National Institutes of Health (NIH) T32GM008396HHS | National Institutes of Health (NIH) T32GM134744HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R21 AR778132Kansas City Consortium on Musculoskeletal DiseasesNIAMS NIH HHS R21 AR077813NIGMS NIH HHS T32 GM008396NIGMS NIH HHS T32 GM135744The Ryan Foundation (Wayne L. Ryan Fellowship)University of Missouri Veterinary Research Scholars Program, Boehringer IngelheimVaeterans Administration Shared Equipment Evaluation Program (ShEEP)
6 · The paper itself
Abstract
Osteogenesis imperfecta (OI) is a heritable connective tissue disorder with marked skeletal fragility and increased recognition as a pleiotropic type I collagenopathy. The impact of OI-causing gene variants on cardiac health and lifespan is just beginning to be understood. To begin to investigate cardiac manifestations of OI-causing type I collagen variants, we utilized the osteogenesis imperfecta murine (
Indexed as
AgingAortic Valve StenosisCollagen Type IMyocardiumOsteogenesis ImperfectaVentricular Function, LeftAdultAge FactorsAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLCollagen Type Icardiacmouse modelosteogenesis imperfectasexual dimorphismtype I collagen
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cardiac health, type I collagen, and aging in the · full record | OpenQuestion